TW202204343A - 經取代之3-苯氧基氮雜環丁烷-1-基-吡 - Google Patents

經取代之3-苯氧基氮雜環丁烷-1-基-吡 Download PDF

Info

Publication number
TW202204343A
TW202204343A TW110111402A TW110111402A TW202204343A TW 202204343 A TW202204343 A TW 202204343A TW 110111402 A TW110111402 A TW 110111402A TW 110111402 A TW110111402 A TW 110111402A TW 202204343 A TW202204343 A TW 202204343A
Authority
TW
Taiwan
Prior art keywords
group
μmol
schizophrenia
mixture
room temperature
Prior art date
Application number
TW110111402A
Other languages
English (en)
Chinese (zh)
Inventor
凱 傑拉齊
芭芭拉 伯塔尼
馬可 弗拉拉
賈科莫 弗薩蒂
史考特 哈柏森
猶他 費德瑞克 萊塞爾
法蘭克 藍吉
格瑞米 山波
維埃拉 烏蘇拉 穆勒
朱利安 衛皮奇
易峰 熊
Original Assignee
德商百靈佳殷格翰國際股份有限公司
美商艾尼納製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商百靈佳殷格翰國際股份有限公司, 美商艾尼納製藥公司 filed Critical 德商百靈佳殷格翰國際股份有限公司
Publication of TW202204343A publication Critical patent/TW202204343A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW110111402A 2020-03-30 2021-03-29 經取代之3-苯氧基氮雜環丁烷-1-基-吡 TW202204343A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
US63/001,640 2020-03-30

Publications (1)

Publication Number Publication Date
TW202204343A true TW202204343A (zh) 2022-02-01

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110111402A TW202204343A (zh) 2020-03-30 2021-03-29 經取代之3-苯氧基氮雜環丁烷-1-基-吡

Country Status (20)

Country Link
US (1) US11780827B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126850B1 (cg-RX-API-DMAC7.html)
JP (1) JP7617134B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220161454A (cg-RX-API-DMAC7.html)
CN (1) CN115697997B (cg-RX-API-DMAC7.html)
AR (1) AR121675A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021250303A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018996A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176265A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014886A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220554A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000203A (cg-RX-API-DMAC7.html)
EC (1) ECSP22080683A (cg-RX-API-DMAC7.html)
IL (1) IL296823A (cg-RX-API-DMAC7.html)
JO (1) JOP20220235A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022012067A (cg-RX-API-DMAC7.html)
PE (1) PE20221918A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552553A1 (cg-RX-API-DMAC7.html)
TW (1) TW202204343A (cg-RX-API-DMAC7.html)
WO (1) WO2021198149A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
WO2023041432A1 (en) 2021-09-14 2023-03-23 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
CN119143731B (zh) * 2024-09-13 2025-08-26 中国海洋大学 一种吡嗪酰胺类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2361149A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Aromatic amides
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
EP2518054A1 (en) * 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
MX373876B (es) * 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Also Published As

Publication number Publication date
AU2021250303A1 (en) 2022-09-22
US11780827B2 (en) 2023-10-10
IL296823A (en) 2022-11-01
JOP20220235A1 (ar) 2022-09-28
MX2022012067A (es) 2022-10-13
DOP2022000203A (es) 2022-11-30
ECSP22080683A (es) 2022-11-30
CA3176265A1 (en) 2021-10-07
CO2022014886A2 (es) 2022-10-31
PE20221918A1 (es) 2022-12-29
KR20220161454A (ko) 2022-12-06
JP2023522307A (ja) 2023-05-30
BR112022018996A2 (pt) 2022-11-01
WO2021198149A1 (en) 2021-10-07
CN115697997B (zh) 2024-07-30
EP4126850B1 (en) 2024-04-17
AR121675A1 (es) 2022-06-29
EP4126850A1 (en) 2023-02-08
US20220356172A1 (en) 2022-11-10
CR20220554A (es) 2023-01-09
CN115697997A (zh) 2023-02-03
PH12022552553A1 (en) 2024-01-03
JP7617134B2 (ja) 2025-01-17

Similar Documents

Publication Publication Date Title
US9133122B2 (en) Amide compounds, compositions and uses thereof
KR20210098960A (ko) Helios의 소분자 분해제 및 사용 방법
US9932335B2 (en) Pyrrolopyridine or pyrazolopyridine derivatives
JP7846113B2 (ja) 置換ピペリジノ化合物及び関連する治療方法
WO2004110986A1 (ja) ベンズアミド誘導体又はその塩
AU2018216040A1 (en) OGA inhibitor compounds
CA2570197C (en) Nk1 antagonists
EA035544B1 (ru) Производные тетрагидроизохинолина
EA025322B1 (ru) Производные дигидробензооксазина и дигидропиридооксазина
JP6876625B2 (ja) Nr2bnmdaレセプターアンタゴニストとしての3,3−ジフルオロピペリジンカルバメート複素環式化合物
TW201514154A (zh) 適用於治療對多巴胺d3受體調節有反應的病症之醯胺基環烷基化合物
CN110248949B (zh) 免疫蛋白酶体抑制剂
JP7617134B2 (ja) Gpr52アゴニスト活性を有する置換3-フェノキシアゼチジン-1-イル-ピラジン
KR20130122531A (ko) Mglur5 양성 알로스테릭 조절물로서 치환된 6­메틸니코틴아미드
KR20240013134A (ko) 시그마 리간드로서 피리딘-술폰아미드 유도체
EP4402138B1 (en) 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
WO2024067302A1 (zh) 一种酰胺类化合物及其制备Sigma2和5HT2A抑制剂的用途
EP3810593A1 (en) Oga inhibitor compounds
KR102728343B1 (ko) 이미다조피리딘 유도체 및 이의 약제로서의 용도
JP7200258B2 (ja) デュアルの5-ht2aおよび5-ht6受容体アンタゴニストとしての新しいインドールおよびベンゾイミダゾール誘導体
US7498438B2 (en) Fused ring NK1 antagonists
US20250100981A1 (en) Cis-substituted 5-(hydroxymethyl)morpholine-2-carboxamides as agonists of SSTR4
US20260125359A1 (en) Heteroaryl compounds as multi-target protein kinase inhibitors
CN117820202A (zh) 一种胺基甲酸类化合物及其作为Sigma2和5HT2A双靶标抑制剂的用途
EA042805B1 (ru) Производные имидазопиридина и их применение в качестве лекарственного средства